Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction.
Mohamed T AbuelazmAbdelrahman AttiaMohamed AbdelnabiUzair JafarOmar AlmaadawyMohamed A ElzeftawyAbdelrahman MahmoudKhaled AlbakriBasel AbdelazeemPublished in: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2024)
Vericiguat 10 mg was effective in reducing the composite CVS mortality and HF hospitalization, with an acceptable safety profile. This was only observed in HFrEF patients, but not in HFpEF patients. However, our data regarding other agents (riociguat and praliciguat) and HFpEF can be underpowered, warranting further RCTs to clarify vericiguat 10 mg place in HFrEF management guidelines and to investigate sGC stimulators for HFpEF in large-scale trials.
Keyphrases
- ejection fraction
- end stage renal disease
- heart failure
- aortic stenosis
- chronic kidney disease
- newly diagnosed
- prognostic factors
- type diabetes
- risk factors
- pulmonary hypertension
- randomized controlled trial
- patient reported outcomes
- machine learning
- left ventricular
- cardiovascular disease
- electronic health record
- acute heart failure
- big data
- study protocol
- open label
- double blind